L1CAM expression in endometrial carcinomas: an ENITEC collaboration study

Area of Science:

• Oncology
• Pathology
• Molecular Biology

Background:

• Accurate identification of aggressive endometrioid endometrial carcinomas (EECs) and non-endometrioid carcinomas (NEECs) is crucial for improving patient outcomes.
• L1 cell adhesion molecule (L1CAM) is a known prognostic marker in early-stage EECs, but its role in advanced stages and NEECs requires further investigation.
• This study examines L1CAM expression in a large, clinically relevant cohort of endometrial carcinomas.

Purpose of the Study:

• To analyze L1CAM expression in a diverse cohort of endometrial carcinomas.
• To determine the association between L1CAM expression and clinicopathological features and patient outcomes.
• To evaluate L1CAM's potential as a prognostic marker in different endometrial carcinoma subtypes.

Main Methods:

• Immunohistochemistry was used to assess L1CAM expression in 1199 endometrial carcinomas from the European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centers.
• Positive L1CAM staining was defined as expression in more than 10% of tumor cells.
• Statistical analysis correlated L1CAM expression with clinicopathological characteristics and disease outcomes.

Main Results:

• L1CAM was expressed in 10% of stage I EECs, 18% of advanced-stage EECs, and 75% of NEECs.
• L1CAM expression correlated with advanced stage, lymph node involvement, high tumor grade, non-endometrioid histology, lymphovascular invasion, and distant recurrence.
• L1CAM expression was associated with reduced survival in EECs but not in NEECs.

Conclusions:

• L1CAM expression is a significant predictor of poor prognosis in EECs, but not NEECs.
• L1CAM expression is strongly linked to non-endometrioid histology and distant metastasis.
• L1CAM could enhance postoperative risk stratification for endometrial carcinomas and warrants investigation for preoperative use.